-+ 0.00%
-+ 0.00%
-+ 0.00%

Needham Reiterates Buy on Acadia Pharmaceuticals, Maintains $35 Price Target

Benzinga·10/19/2026 10:07:52
Listen to the news
Needham analyst Ami Fadia reiterates Acadia Pharmaceuticals (NASDAQ:ACAD) with a Buy and maintains $35 price target.